Qingfeng Biochemical Technology (Guangzhou) Co., Ltd. has recently announced the successful acquisition of tens of millions of yuan in Pre-A round financing. The investment comes from Baiyun Fund, a subsidiary under Baiyun Financial Holdings. This influx of capital will be strategically allocated to expedite the comprehensive integration of AI technology and laboratory automation. The funding will support various initiatives, including capacity expansion, model innovation, the establishment of application centers, and the advancement of platform development.

Specializing in life science automation, Qingfeng Biochemical has made a significant breakthrough with its flagship product, the OutStanding large-scale automated pipetting workstation integration platform, which has effectively broken the long-standing foreign technological dominance in this field. With the newly secured funds, Qingfeng Biochemical is poised to further enhance the development of a seamless 'AI + automation' ecosystem and drive forward the intelligent response capabilities of its equipment.